These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36402814)

  • 1. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
    Eule CJ; Flaig TW; Wong K; Graf R; Lam ET
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):188-193. PubMed ID: 36402814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
    Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
    Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Choudhury AD
    Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
    Bhin J; Yemelyanenko J; Chao X; Klarenbeek S; Opdam M; Malka Y; Hoekman L; Kruger D; Bleijerveld O; Brambillasca CS; Sprengers J; Siteur B; Annunziato S; van Haren MJ; Martin NI; van de Ven M; Peters D; Agami R; Linn SC; Boven E; Altelaar M; Jonkers J; Zingg D; Wessels LFA
    J Exp Med; 2023 Nov; 220(11):. PubMed ID: 37642941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
    Cell Death Dis; 2014 Oct; 5(10):e1437. PubMed ID: 25275598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
    Morgan TM; Koreckij TD; Corey E
    Curr Cancer Drug Targets; 2009 Mar; 9(2):237-49. PubMed ID: 19275762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
    Houédé N; Pourquier P
    Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
    Tang KD; Ling MT
    Curr Med Chem; 2014; 21(26):3048-56. PubMed ID: 24735368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.